United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine is contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

cipla limited, india - abacavir sulfate , lamivudine - dispersible tablets - 120/60

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

cipla limited, india - abacavir sulfate , lamivudine - dispersible tablets - 120/60

Uganda - English - National Drug Authority

cipla ltd. - abacavir sulfate + lamivudine - oral solid ordinary orally disintegrating tablets - 120mg + 60mg

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - abacavir sulfate ; lamivudine - film coated tablet - 600mg/300 milligram - lamivudine and abacavir

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - abacavir sulfate 702mg equivalent to abacavir 600 mg;  ;  ; lamivudine 300mg;   - film coated tablet - 600mg/300mg - active: abacavir sulfate 702mg equivalent to abacavir 600 mg     lamivudine 300mg   excipient: magnesium stearate microcrystalline cellulose opadry orange ys-1-13065a sodium starch glycolate - kivexa is a combination of two nucleoside analogues (abacavir and lamivudine). it is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; dolutegravir as sodium; lamivudine - film coated tablets - dolutegravir as sodium 50 mg; abacavir as sulfate 600 mg; lamivudine 300 mg - lamivudine and abacavir and dolutegravir - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults and adolescents above 12 years of age weighing at least 40 kg.before initiating treatment with abacavir-containing products, screening for carriage of the hla-b*5701 allele should be performed in any hiv-infected patient, irrespective of racial origin. abacavir should not be used in patients known to carry the hla-b*5701 allele.

Canada - English - Health Canada

mylan pharmaceuticals ulc - abacavir (abacavir sulfate); lamivudine - tablet - 600mg; 300mg - abacavir (abacavir sulfate) 600mg; lamivudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors

Canada - English - Health Canada

mint pharmaceuticals inc - abacavir (abacavir sulfate); lamivudine - tablet - 600mg; 300mg - abacavir (abacavir sulfate) 600mg; lamivudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. limitation of use: the dosage of this product is for hiv-1 and not for hbv. lamivudine tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the products. pregnancy category c there are no adequate and well-controlled studies of lamivudine tablets in pregnant women. animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. lamivudine tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in south africa. the study assessed pharmacokinetics in: 16 women at 36 week